Alexander R Slusky, Director, on May 28, 2026, sold 60,000 shares in Rocket Lab (RKLB) for $8,964,092. Following the Form 4 filing with the SEC, Slusky has control over a total of 436,006 common shares of the company, with 61,331 shares held directly and 374,675 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1819994/000200101126000082/xslF345X05/edgardoc.xml
Gary D Fields, Director, on May 29, 2026, sold 19,000 shares in Aaon (AAON) for $2,663,800. Following the Form 4 filing with the SEC, Fields has control over a total of 30,751 common shares of the company, with 15,252 shares held directly and 15,499 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/824142/000164282626000011/xslF345X05/wk-form4_1780353195.xml
Jonathan P Faust, Executive Vice President and Chief Financial Officer, on May 29, 2026, sold 10,076 shares in Sanmina (SANM) for $2,678,150. Following the Form 4 filing with the SEC, Faust has control over a total of 77,000 common shares of the company, with 77,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/897723/000110465926069049/xslF345X05/tm2616528-1_4seq1.xml
Andrew Callos, Executive Vice President, Chief Commercial Officer, on June 01, 2026, sold 15,000 shares in Cytokinetics (CYTK) for $1,111,200. Following the Form 4 filing with the SEC, Callos has control over a total of 58,555 common shares of the company, with 58,555 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1061983/000106198326000065/xslF345X05/form4.xml